^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
SelectMDx

Company:
MDxHealth
Type:
CE Marked
Related tests:

Details

Evidence
A non-invasive urine test (“liquid biopsy”), SelectMDx measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1). The test provides binary results that, when combined with the patient’s clinical risk factors, help the physician determine whether: The patient may benefit from a biopsy and early prostate detection, or The patient can avoid a biopsy and return to routine screening
Cancer:
Prostate Cancer
Gene:
DLX1 (Distal-Less Homeobox 1), HOXC6 (Homeobox C6)
Method:
Liquid biopsy
Approvals
Date
Cancer
Gene
Drug
By
10/13/15
CE